Related Experiment Video

Updated: Aug 3, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Continuous insulin infusion in hyperglycaemic extremely-low- birth-weight neonates

Sze May Ng1, Judith E May, Anthony J B Emmerson

  • 1Neonatal Medical Unit, St Mary's Hospital, Manchester, UK. ngszemay@yahoo.com

Biology of the Neonate
|February 8, 2005
PubMed

Insights

Continuous insulin infusion effectively treats neonatal hyperglycemia. Extremely-low-birth-weight infants require longer treatment durations and higher insulin doses compared to larger neonates.

Area of Science:

  • Neonatalogy
  • Endocrinology
  • Pediatric Intensive Care

Background:

  • Neonatal hyperglycemia is often linked to impaired gluconeogenesis inhibition and insulin resistance in premature infants.
  • Understanding glucose regulation is crucial for managing hyperglycaemia in vulnerable newborns.

Purpose of the Study:

  • To compare the effectiveness and response rate of continuous insulin infusion for hyperglycaemic neonates.
  • To evaluate outcomes in extremely-low-birth-weight (ELBW) neonates (< or =1,000 g) versus larger birth weight (LBW) neonates (>1,000 g).

Main Methods:

  • 115 neonates with hyperglycemia were treated with a standard exogenous insulin infusion protocol.
  • Continuous insulin infusion efficiency was assessed by comparing ELBW infants to LBW infants.
  • Data collected included duration of infusion, insulin dosage, and blood glucose levels.

Main Results:

  • ELBW neonates required significantly longer insulin infusion durations (p < 0.0001).
  • ELBW neonates needed significantly higher average insulin infusion rates (units/kg/h) (p < 0.0001).
  • No significant differences were observed in dextrose tolerance, age at infusion initiation, or average blood glucose.

Conclusions:

  • Continuous insulin infusion is a safe and effective treatment for persistent neonatal hyperglycemia.
  • ELBW neonates exhibit a slower response to insulin therapy and require higher doses.
  • Tailored treatment protocols may be necessary to optimize glucose normalization in ELBW infants.
Abstract

More Related Videos

A Model of Chronic Nutrient Infusion in the Rat08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs08:58

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs

Published on: October 31, 2025

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Hyperosmolar Hyperglycemic State01:21

Hyperosmolar Hyperglycemic State

Hyperosmolar Hyperglycemic State, or HHS, is a serious and life-threatening complication of type 2 diabetes mellitus. It is characterized by three main features: severe hyperglycemia, profound dehydration, and elevated serum osmolality, all occurring without significant ketoacidosis.HHS typically develops in older adults or individuals with limited access to fluids. This may result from illness, cognitive impairment, or medications such as diuretics or corticosteroids. These factors reduce...